Merz Pharmaceutical seems poised to become a leader in the U.S. as a provider of aesthetic medicine. Yesterday the company announced FDA approval for NT-201, a drug now known as XEOMIN. Along with the relatively new Dysport and popular Botox®, it’s the 3rd botulinum toxin to receive FDA approval for treating cervical dystonia and blepharospasm.
According to a company press release “XEOMIN does not require refrigeration prior to reconstitution,” a difference they say could “simplify product distribution and storage, and help ensure product integrity at the time of injection.”
Earlier this year, Merz announced the acquisition of California based Bioform Medical, maker of the popular Radiesse dermal filler. They say it’s a transaction that “advances Merz’s strategy of becoming a leading player in aesthetic medicine.” Once the transaction is complete, Bioform will be renamed Merz Aesthetics and two new dermal fillers will be introduced: Belotero® and Novabel®.
Read more about Radiesse treatment in Grand Rapids, Michigan
